ClearPoint Neuro (NASDAQ: CLPT) director sells stock, granted 12,820 RSUs

(Moderate)

(Negative)

Form Type

Rhea-AI Filing Summary

ClearPoint Neuro director Matthew B. Klein reported mixed equity activity. On May 21, 2026, he completed an open-market sale of 16,000 shares of common stock at a weighted average price of $11.59 per share and held 46,935 shares directly afterward. The sale prices ranged from $11.57 to $11.65.

On the same date, he received a grant of 12,820 restricted stock units (RSUs), each representing a contingent right to one share of ClearPoint Neuro common stock. These RSUs vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders.

Insights

Director sold shares while receiving a new RSU grant, a routine mix of liquidity and compensation.

Director Matthew B. Klein executed an open-market sale of 16,000 common shares at a weighted average of $11.59, retaining 46,935 shares afterward. This is paired with a compensation-related grant of 12,820 RSUs, not a market purchase.

The RSUs convert one-for-one into common stock and vest on the earlier of the first grant anniversary or just before the 2027 annual meeting. With no derivative positions listed as remaining, this filing mainly updates his equity mix. The overall pattern appears routine and compensation-driven.

Insider Trade Summary

Net Seller: 16,000 shares

Net Sell 2 txns

Insider Klein Matthew B.

Role Director

Sold 16,000 shs ($185K)

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	12,820	$0.00	$0.00
Sale	Common Stock	16,000	$11.59	$185K

Holdings After Transaction: Restricted Stock Units — 12,820 shares (Direct); Common Stock — 46,935 shares (Direct)

Footnotes (3)

F1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.57 to $11.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
F3. The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/26/2026 - 04:30 PM

FAQ

What insider transactions did ClearPoint Neuro (CLPT) director Matthew B. Klein report?

Matthew B. Klein reported an open-market sale of 16,000 shares of ClearPoint Neuro common stock and a grant of 12,820 restricted stock units. The filing shows both liquidity activity and new equity-based compensation on the same date.

How many ClearPoint Neuro (CLPT) shares did Matthew B. Klein sell and at what price?

He sold 16,000 shares of ClearPoint Neuro common stock at a weighted average price of $11.59 per share. The individual trade prices ranged between $11.57 and $11.65, according to the transaction footnote.

What are the terms of the 12,820 restricted stock units granted to Matthew B. Klein at CLPT?

Klein received 12,820 restricted stock units, each representing a contingent right to one share of ClearPoint Neuro common stock. These RSUs vest on the earlier of the first anniversary of the grant date or the day immediately before the company’s 2027 annual meeting.

How many ClearPoint Neuro (CLPT) shares does Matthew B. Klein hold after the reported sale?

After selling 16,000 shares, Klein directly holds 46,935 shares of ClearPoint Neuro common stock. This figure reflects his direct ownership position immediately following the reported transaction on May 21, 2026.

Is Matthew B. Klein’s RSU grant in the CLPT Form 4 a market purchase?

No, the 12,820 restricted stock units are a grant classified as a compensation-related acquisition. They are not bought in the open market and instead vest into common shares based on the time and meeting-based vesting conditions described.

When will Matthew B. Klein’s newly granted CLPT RSUs vest?

The RSUs will vest on the earlier of two dates: the first anniversary of the grant date or the day immediately preceding ClearPoint Neuro’s 2027 annual meeting of stockholders. Vesting converts each unit into one share of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Matthew B.

(Last)

(First)

(Middle)

C/O CLEARPOINT NEURO, INC

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH

CALIFORNIA

92075

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		S		16,000	D	$11.59⁽¹⁾	46,935	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	05/21/2026		A		12,820		⁽³⁾	⁽³⁾	Common Stock	12,820	$0	12,820	D

Explanation of Responses:

1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.57 to $11.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

2. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

3. The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders.

	/s/ Danilo D'Alessandro, by Power of Attorney for Matthew B. Klein	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR